Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

570 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Lada P, Prados M, Goldin J, Wen PY, Cloughesy T. Pope WB, et al. Among authors: prados m. J Neurooncol. 2012 Jul;108(3):491-8. doi: 10.1007/s11060-012-0847-y. Epub 2012 Mar 18. J Neurooncol. 2012. PMID: 22426926 Free PMC article.
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Wefel JS, et al. Among authors: prados m. Neuro Oncol. 2011 Jun;13(6):660-8. doi: 10.1093/neuonc/nor024. Epub 2011 May 9. Neuro Oncol. 2011. PMID: 21558074 Free PMC article. Clinical Trial.
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF. Nghiemphu PL, et al. Among authors: prados m. J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7. J Neurooncol. 2018. PMID: 28988377 Free PMC article. Clinical Trial.
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Ellingson BM, et al. Among authors: prados m. Neuro Oncol. 2018 Aug 2;20(9):1240-1250. doi: 10.1093/neuonc/noy053. Neuro Oncol. 2018. PMID: 29660006 Free PMC article. Clinical Trial.
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M. Cloughesy TF, et al. Among authors: prados m. J Clin Oncol. 2005 Sep 20;23(27):6647-56. doi: 10.1200/JCO.2005.10.068. J Clin Oncol. 2005. PMID: 16170172 Clinical Trial.
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Vredenburgh JJ, et al. Among authors: prados m. Oncologist. 2010;15(12):1329-34. doi: 10.1634/theoncologist.2010-0105. Epub 2010 Dec 8. Oncologist. 2010. PMID: 21147867 Free PMC article. Clinical Trial.
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Butowski N, et al. Among authors: prados m. Neuro Oncol. 2016 Apr;18(4):557-64. doi: 10.1093/neuonc/nov245. Epub 2015 Oct 8. Neuro Oncol. 2016. PMID: 26449250 Free PMC article. Clinical Trial.
570 results